Draft:Xenon Pharmaceuticals
| Submission declined on 26 April 2024 by KylieTastic (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Company type | Public |
|---|---|
| Nasdaq: XENE | |
| Founded | 5 November 1996 in Burnaby, British Columbia, Canada |
| Founder | Simon Pimstone, Johannes Kastelein, Michael Hayden |
| Headquarters | Burnaby, British Columbia , Canada |
| Products |
Xenon Pharmaceuticals is a biopharmaceutical company that is focused on improving the lives of neurological and psychiatric disorders. As of December 31st of 2023, Xenon Pharmaceuticals has 259 employees,[1] a reported increase of 46 employees since the previous year.
Founded in 1996 by Simon Pimstone, Johannes Kastelein, and Michael Hayden, Xenon Pharmaceuticals is currently headquartered in Burnaby, Canada, although it has operations in Vancouver, Canada and Boston, Massachusetts, USA.[2]
Since then, the company has been pushing out clinical trials for several drugs in its pipeline, such as XEN1101 for focal onset seizures and generalized tonic-clonic seizures (both currently in phase III clinical trials), XEN1101 for MDD, also with an investigator-led collaboration study with Mount Sinai, both of which are waiting for approval to go into Phase III clinical trials. There are also phase II clinical trials underway with Neurocrine Biosciences for NBI-921352 (formerly XEN901) for treating patients with SCN8A and EEIE.[3]
It has also dropped clinical trials for drugs either due to being acquired by another company or for other reasons, such as Funapide (formerly TV-45070 and XEN402), which has no current plans for going into phase III clinical trials, according to Pacira Biosciences' pipeline after acquiring Flexion Therapeutics in Oct. 2021.[4]
References[edit]
External links[edit]
Category:Pharmaceutical companies of Canada Category:Companies listed on the Nasdaq